Helixmith Overview
- Founded
- 1996
- Status
- Public
- Employees
- 113
- Stock Symbol
- 084990
- Investments
- 2
- Share Price
- $15.99
- (As of Thursday Closing)
Helixmith General Information
Description
Helixmith Co Ltd, formerly ViroMed Co Ltd is active in the healthcare sector in Korea. The company specializes in developing pharmaceutical products for the treatment of diseases related to peripheral artery, coronary artery, cardiovascular system and neuropathy, cancer and allergy. Its suite of products includes protein/deoxyribonucleic acid (DNA)-based biopharmaceuticals, botanical drugs and natural pharmaceuticals.
Contact Information
Website
www.helixmith.com
Formerly Known As
ViroMedica Pacific
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
KRX
Primary Office
- 5th Floor, Building 203, SNU
- No. 599 Gwanak-ro, Gwanak-gu
- Seoul, 151-747
- South Korea
Helixmith Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $15.99 | $16.85 | $15.95 - $34.01 | $602M | 37.7M | 189K | -$1.21 |
Helixmith Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 |
|---|---|---|---|---|
| EV | 570,658 | 873,599 | 1,654,302 | 3,596,774 |
| Revenue | 2,202 | 3,646 | 3,820 | 2,845 |
| EBITDA | (42,942) | (56,390) | (87,717) | (26,532) |
| Net Income | (41,309) | (70,176) | (91,793) | (26,138) |
| Total Assets | 258,721 | 438,288 | 320,662 | 254,166 |
| Total Debt | 25,777 | 137,093 | 111,104 | 73,212 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Helixmith Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Helixmith‘s full profile, request access.
Request a free trialHelixmith Patents
Helixmith Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200271647-A1 | Biomarkers for predicting prognosis of kidney disease | Pending | 19-Dec-2018 | 00000000000 | |
| EP-3888669-A1 | Composition for preventing or treating metabolic bone diseases or menopausal symptoms | Pending | 28-Nov-2018 | 0000000000 | |
| EP-3882267-A1 | Anti-c-met antibody showing enhanced stability or antigen-binding fragments thereof | Pending | 14-Nov-2018 | 00000000000 | |
| US-20200023075-A1 | Lyophilized pharmaceutical compositions for naked dna gene therapy | Pending | 19-Jul-2018 | 00000000 | |
| CA-3106297-A1 | Lyophilized pharmaceutical compositions for naked dna gene therapy | Pending | 19-Jul-2018 | A61K48/0091 |
Helixmith Executive Team (3)
Helixmith Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Jong-Mook Kim Ph.D | Helixmith | Founder, Chief Executive Officer & Board Member | 000 0000 |
Helixmith Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialHelixmith Investments (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 (000 00 | 20-Aug-2018 | 000000000 | Buildings and Property | 00000000 | |
| Wacker Biotech US | 01-Aug-2018 | Joint Venture | BPO/Outsource Services |
Helixmith Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000 0000000 00 | 01-Aug-2018 | 00000 0000000 | Completed |
|